search
Back to results

Epidermal Skin Grafts to Improve Healing In Radiation Wounds

Primary Purpose

Radiation Dermatitis

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CelluTomeTM Epidermal Harvesting System
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Radiation Dermatitis focused on measuring Epidermal graft, Skin graft, Radiation wound

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Status post radiation treatment, with radiation-induced wound. This includes patient with moist desquamation as well as full epidermal necrosis and superficial dermal ulcerations, this wound would otherwise be allowed to heal by secondary intention;
  • Having suitable areas of treatment: All wounds in the area of interest must be at least 20 cm2 (~10 cm2 per treatment/control area);
  • The radiation injury must have a suitable adjacent irradiated control site before initiation of treatment. This will be determined by objective measurements of % wound epithelization, wound erythema, pliability, induration and thickness at enrollment;
  • Able and willing to comply with all visit, treatment and evaluation schedules and requirements;
  • Wound considered appropriate by physician to receive epidermal grafting;
  • Able to understand and provide written informed consent;

Exclusion Criteria:

  • Active tanning, including the use of tanning booths, during the course of the study;
  • Study wound exhibits clinical signs and symptoms of infection at the screening/enrollment visit;
  • Patient unable to provide donor site for epidermal harvesting;
  • Wound sites located on the face, hands or feet
  • Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists;
  • History of collagen vascular disease;
  • Active Herpes Simplex or Zoster at the time of treatment or having experienced more than three episodes of Herpes Simplex / Zoster eruption within a year of study enrollment;
  • History of immunosuppression/immune deficiency disorders (including human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) or use of immunosuppressive medications;
  • Significant concurrent illness, such as uncontrolled diabetes (with a hemoglobin A1C of more than 8) (i.e., any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process);
  • Mentally incompetent, prisoner or evidence of active substance or alcohol abuse;
  • Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or study personnel) to treat the subject as part of this research study;
  • Participation in another interventional study with potential exposure to an investigational drug within past 30 days;
  • Pregnant females, due to possible discomfort with the procedure even though the procedure is localized and there is no new drug.

Sites / Locations

  • Massachusetts General Hospital, Wellman Center for PhotomedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Epidermal Grafting

No treatment

Arm Description

This irradiated area of the skin will be treated with autologous epidermal grafts

This irradiated area will not receive any treatment

Outcomes

Primary Outcome Measures

Change in the CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events v5) grading
Patients will receive a grading for their treated radiation wound based on the CTCAE. Changes in the grading over time will be used to assess improvement of the wound

Secondary Outcome Measures

Full Information

First Posted
September 17, 2020
Last Updated
October 20, 2023
Sponsor
Massachusetts General Hospital
Collaborators
3M
search

1. Study Identification

Unique Protocol Identification Number
NCT04560803
Brief Title
Epidermal Skin Grafts to Improve Healing In Radiation Wounds
Official Title
Using Autologous Epidermal Skin Micrografts to Improve Healing In Radiation Wounds: A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 19, 2021 (Actual)
Primary Completion Date
March 2028 (Anticipated)
Study Completion Date
December 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
3M

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients undergoing radiation for the treatment of malignancies may suffer from side effects to the skin in the form of radiation dermatitis. This can lead to local wound formation with poor healing. Treatment options for the resulting wound can range from watchful waiting to more aggressive debridement and secondary grafting. Epidermal grafting is a technique in which autologous epidermis is used to cover wounds that are larger than the donor site. Previous studies have demonstrated that this is an effective treatment for different wounds and ulcers but its utility has not yet been evaluated for the treatment of radiation induced injuries. The CelluTome Epidermal Grafting System is a semi automated device that allows easy formation of epidermal Blister. Our study will evaluate the efficacy of epidermal grafts collected using the CelluTome device in the treatment of radiation dermatitis.
Detailed Description
Patients participating in this study will undergo the epidermal grafting procedure to a part of their radiation-induced wound. The remaining untreated area will serve as an irradiated control. The donor tissue will be collected from normal skin in the upper thigh area. In addition to their primary screening visit, patients will be followed up closely in a series of 9 study visits. During these sessions, photographs will be taken and patients will be asked to fill out questionnaires.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Radiation Dermatitis
Keywords
Epidermal graft, Skin graft, Radiation wound

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
34 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Epidermal Grafting
Arm Type
Experimental
Arm Description
This irradiated area of the skin will be treated with autologous epidermal grafts
Arm Title
No treatment
Arm Type
No Intervention
Arm Description
This irradiated area will not receive any treatment
Intervention Type
Device
Intervention Name(s)
CelluTomeTM Epidermal Harvesting System
Intervention Description
Autologous epidermal grafts that will be placed at the treatment site
Primary Outcome Measure Information:
Title
Change in the CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events v5) grading
Description
Patients will receive a grading for their treated radiation wound based on the CTCAE. Changes in the grading over time will be used to assess improvement of the wound
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Status post radiation treatment, with radiation-induced wound. This includes patient with moist desquamation as well as full epidermal necrosis and superficial dermal ulcerations, this wound would otherwise be allowed to heal by secondary intention; Having suitable areas of treatment: All wounds in the area of interest must be at least 20 cm2 (~10 cm2 per treatment/control area); The radiation injury must have a suitable adjacent irradiated control site before initiation of treatment. This will be determined by objective measurements of % wound epithelization, wound erythema, pliability, induration and thickness at enrollment; Able and willing to comply with all visit, treatment and evaluation schedules and requirements; Wound considered appropriate by physician to receive epidermal grafting; Able to understand and provide written informed consent; Exclusion Criteria: Active tanning, including the use of tanning booths, during the course of the study; Study wound exhibits clinical signs and symptoms of infection at the screening/enrollment visit; Patient unable to provide donor site for epidermal harvesting; Wound sites located on the face, hands or feet Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists; History of collagen vascular disease; Active Herpes Simplex or Zoster at the time of treatment or having experienced more than three episodes of Herpes Simplex / Zoster eruption within a year of study enrollment; History of immunosuppression/immune deficiency disorders (including human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) or use of immunosuppressive medications; Significant concurrent illness, such as uncontrolled diabetes (with a hemoglobin A1C of more than 8) (i.e., any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process); Mentally incompetent, prisoner or evidence of active substance or alcohol abuse; Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or study personnel) to treat the subject as part of this research study; Participation in another interventional study with potential exposure to an investigational drug within past 30 days; Pregnant females, due to possible discomfort with the procedure even though the procedure is localized and there is no new drug.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Katie Vogel
Phone
6177242168
Email
kevogel@mgh.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Elizabeth Morehouse
Phone
6177242168
Email
emorehouse@partners.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yen-Lin E Chen, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital, Wellman Center for Photomedicine
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katie Vogel
Phone
617-724-2168
Email
kevogel@mgh.harvard.edu
First Name & Middle Initial & Last Name & Degree
Elizabeth Morehouse
Phone
6177242168
Email
emorehouse@partners.org

12. IPD Sharing Statement

Learn more about this trial

Epidermal Skin Grafts to Improve Healing In Radiation Wounds

We'll reach out to this number within 24 hrs